As outlined above, according to the SPC, most of the NSCLC drugs were approved for pretreated patients (18 dossiers [6–9, 11–13, 17–19, 21, 23, 25, 27, 33, 35, 37, 39, 41]); 11 of these dossiers provided further specifications [8, 9, 12, 13, 21, 23, 25, 33, 35, 39, 41], such as “after prior chemotherapy”, “after platinum-based chemotherapy”, “previously treated with crizotinib” or “prior treatment with EGFR-TKI”. Here, EGFR is linked to non-small cell lung carcinoma.